synergistic activity of alnuctamab and celmods in multiple myeloma preclinical models
Published 1 year ago • 91 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
1:17
antitumor activity of alnuctamab in combination with celmods in multiple myeloma preclinical models
-
2:25
pre-clinical activity of ucartcs1 in multiple myeloma
-
1:59
the growing importance of celmods in the treatment of r/r multiple myeloma
-
2:31
benefits of celmods over imids in multiple myeloma
-
1:55
recent updates on celmods in multiple myeloma
-
1:33
novel targets being explored in multiple myeloma and the value of celmods
-
4:00
potent pre-clinical and early phase activity of inobrodib in multiple myeloma
-
9:25
mgus diagnosis: a step-by-step approach
-
31:15
multiple myeloma in 2023: what patients & caregivers need to know now! | the patient story
-
22:21
tecvayli (teclistamab) everything you need to know
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
1:40
vulnerabilities in lipid synthesis pathways and resistance to imids and celmods in multiple myeloma
-
1:14
the potential of celmods for the treatment of r/r multiple myeloma
-
3:13
how to optimally sequence agents in the expanding treatment armamentarium of multiple myeloma
-
1:08
the impact of extramedullary multiple myeloma on outcomes with ide-cel
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
2:03
activating the immune system with celmods to treat multiple myeloma
-
1:29
insights into the biology of high-risk myeloma and advances being made in this space
-
2:42
hdac8: a novel therapeutic target in multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
0:36
the potential of immunotherapies in the myeloma treatment landscape